The Haemato Oncology Foundation for Adults in the Netherlands (HOVON) has designed this study. Researchers (all doctors) are conducting the study at various hospitals in the Netherlands, Denmark and Sweden.
The study medicines pirtobrutinib and epcoritamab that are used in this study are made available by pharmaceutical companies Eli Lilly and AbbVie. This study is also funded by AbbVie and Eli Lilly.
HOVON needs 70 participants for this study.
The purpose of this study is to find out how safe and effective the combination of pirtobrutinib tablets and subcutaneous epcoritamab is for patients with CLL whose disease has come back after previous treatment or whose disease did not respond well to the previous treatment. The goal is to suppress the CLL to such an extent that the disease does not come back for a long time.
Documented relapsed or refractory CLL or SLL (SLL in Cohort Expansion only) following at least one systemic 1st-line treatment
Requiring treatment according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria;
Age at least 18 years;
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-2;
None
Single group
pirtobrutinib combined with epcoritamab
Combination productcombination treatment
To evaluate efficacy in terms of Progression-free survival (PFS)
To evaluate efficacy in terms of Progression-free survival (PFS) at 24 months after first dose of pirtobrutinib.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
